A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects
2022년 2월 13일 업데이트: Ark Biosciences Inc.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects
This is a randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ziresovir following a single ascending oral dose administration in healthy adult subjects under fasted conditions.
연구 개요
상세 설명
Up to 3 dose cohorts are planned. The ziresovir dose level of each cohort is determined based on the collective clinical and nonclinical data of ziresovir.
The proposed dose levels of Cohorts 1, 2 and 3 are 300 mg and up to 600 mg and up to 900 mg, respectively.
A total of up to 24 subjects will be randomized with 18 subjects to receive active drug and 6 subjects to receive placebo in a double-blind fashion. Eight subjects will be randomized in each dose cohort, with 6 subjects to receive active drug and 2 subjects o receive placebo.
연구 유형
중재적
등록 (실제)
24
단계
- 1단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
New Jersey
-
Secaucus, New Jersey, 미국, 07094
- Frontage
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 (성인)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Capable of giving written informed consent and complying with study procedures;
- Between the ages of 18 and 55 years, inclusive;
- Body mass index (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg;
- Female subjects must have a negative pregnancy test result at screening;
- Considered healthy by the Investigator, based on subject's reported medical history, full physical examination, 12-lead ECG, and vital signs;
- Willing and being able to adhere to study restrictions and to be confined at the Clinical Research Unit.
Exclusion Criteria:
- Clinically significant reported history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity as determined by the Investigator;
- Poor venous access;
- Taken an investigational drug or participated in a clinical trial evaluating an investigational drug or device within 30 days (or 5 half-lives) prior to the study drug dose, whichever is longer;
- Taken any prescription medications within 14 days or 5 half-lives (whichever is longer) of the study drug dose;
- Major surgery or hospitalization within 6 months prior to screening that in the Investigator's opinion would put the subject or study conduct at risk, or have any scheduled surgery or hospitalization during the study period;
- Any condition or finding that in the Investigator's opinion would put the subject or study conduct at risk if the subject were to participate in the study.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: ziresovir
The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast. Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:
|
Planned treatments are:
다른 이름들:
|
|
위약 비교기: placebo
The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast. Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows:
|
Planned treatments are:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
numbers of all AEs
기간: through study completion, an average of 22 days
|
The Common Terminology Criteria for Adverse Events (CTCAE) Version 5 will be used to grade AEs
|
through study completion, an average of 22 days
|
|
percentages of all AEs
기간: through study completion, an average of 22 days
|
The Common Terminology Criteria for Adverse Events (CTCAE) Version 5 will be used to grade AEs
|
through study completion, an average of 22 days
|
|
change from baseline in systolic and diastolic blood pressure
기간: screen/day -1/day 1/day 2/day 3/day4
|
blood pressure in millimeter of mercury
|
screen/day -1/day 1/day 2/day 3/day4
|
|
change from baseline in pulse rate
기간: screen/day -1/day 1/day 2/day 3/day4
|
pulse rate in times per minute
|
screen/day -1/day 1/day 2/day 3/day4
|
|
change from baseline in respiratory rate
기간: screen/day -1/day 1/day 2/day 3/day4
|
respiratory rate in times per minute
|
screen/day -1/day 1/day 2/day 3/day4
|
|
change from baseline in oral temperature
기간: screen/day -1/day 1/day 2/day 3/day4
|
oral temperature in degree
|
screen/day -1/day 1/day 2/day 3/day4
|
|
change from baseline in Prothrombin time/International Normalized Ratio
기간: screen/day -1/day 2/day4
|
INR is calculated from the PT and allows for worldwide standardization of results.
|
screen/day -1/day 2/day4
|
|
change from baseline in Thrombin time
기간: screen/day -1/day 2/day4
|
Thrombin time in seconds
|
screen/day -1/day 2/day4
|
|
change from baseline in activated Partial Thromboplastin time
기간: screen/day -1/day 2/day4
|
activated Partial Thromboplastin time in seconds
|
screen/day -1/day 2/day4
|
|
change from baseline in Hemoglobin (Hgb) count
기간: screen/day -1/day 2/day4
|
Hemoglobin (Hgb) in gram per liter
|
screen/day -1/day 2/day4
|
|
change from baseline in Hematocrit (Hct)
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in Platelet count
기간: screen/day -1/day 2/day4
|
Platelet count per liter
|
screen/day -1/day 2/day4
|
|
change from baseline in Red blood cell (RBC) count
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in White blood cell (WBC) count with differential
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in Specific gravity from urinalysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in pH from urinalysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in Protein from urinalysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in Glucose from urinalysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in Ketones from urinalysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in Bilirubin from urinalysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in Blood from urinalysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in Nitrites from urinalysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in Leukocytes from urinalysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in Urobilinogen from urinalysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
Incidence of abnormal Microscopic urine analysis
기간: screen/day -1/day 2/day4
|
screen/day -1/day 2/day4
|
|
|
change from baseline in heart rate-corrected QT interval from resting 12-lead ECGs
기간: screen/day -1/day1/day2/day4
|
ECGs will be performed after the subject has been supine for at least 5 minutes
|
screen/day -1/day1/day2/day4
|
|
change from baseline in heart rate from resting 12-lead ECGs
기간: screen/day -1/day1/day2/day4
|
ECGs will be performed after the subject has been supine for at least 5 minutes
|
screen/day -1/day1/day2/day4
|
|
change from baseline in QRS intervals from resting 12-lead ECGs
기간: screen/day -1/day1/day2/day4
|
ECGs will be performed after the subject has been supine for at least 5 minutes
|
screen/day -1/day1/day2/day4
|
|
change from baseline in treatment-emergent T-wave morphology from resting 12-lead ECGs
기간: screen/day -1/day1/day2/day4
|
ECGs will be performed after the subject has been supine for at least 5 minutes
|
screen/day -1/day1/day2/day4
|
|
change from baseline in appearance of U-waves from resting 12-lead ECGs
기간: screen/day -1/day1/day2/day4
|
ECGs will be performed after the subject has been supine for at least 5 minutes
|
screen/day -1/day1/day2/day4
|
|
Incidence of abnormal physical findings
기간: screen/day -1/day2/day3/day4
|
full physical examination will be conducted at screening and an abbreviated physical exam will be conducted on Day -1 and Day 2. A symptom-directed physical exam will be conducted on Day 3 and Day 4.
|
screen/day -1/day2/day3/day4
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
To characterize the drug concentration of ziresovir following single ascending doses by oral administration in healthy adult male and female subjects
기간: 0 (within 90 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72 hours post-dose
|
0 (within 90 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72 hours post-dose
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
- 연구 책임자: Jimmy Gu, Ark Biosciences
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2021년 3월 24일
기본 완료 (실제)
2021년 6월 14일
연구 완료 (실제)
2021년 7월 22일
연구 등록 날짜
최초 제출
2021년 2월 1일
QC 기준을 충족하는 최초 제출
2021년 3월 4일
처음 게시됨 (실제)
2021년 3월 9일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2022년 2월 15일
QC 기준을 충족하는 마지막 업데이트 제출
2022년 2월 13일
마지막으로 확인됨
2022년 2월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .